<--- Back to Details
First PageDocument Content
Amines / Pharmacology / Amphetamines / Dissociative drugs / NMDA receptor antagonists / Animal model of depression / Dextroamphetamine / Antidepressant / Imipramine / Medicine / Chemistry / Euphoriants
Date: 2015-04-07 16:01:33
Amines
Pharmacology
Amphetamines
Dissociative drugs
NMDA receptor antagonists
Animal model of depression
Dextroamphetamine
Antidepressant
Imipramine
Medicine
Chemistry
Euphoriants

Microsoft Word - Session_03_Psychopharmacology.doc

Add to Reading List

Source URL: www.sbfte.org.br

Download Document from Source Website

File Size: 249,87 KB

Share Document on Facebook

Similar Documents

NEW DRUG: Vilazodone (Viibryd®) Dan Anderson Los Angeles County Department of Coroner, 1104 N. Mission Road, Los Angeles, CAVilazodone (Viibyrd®) is a new antidepressant approved

DocID: 1u71J - View Document

NutraHacker Depression Side Effects Report for Customer: 16b3a1d2-1cc8-4b35-972c-b83fceb0a109 Instructions: This report analyzes polymorphisms that have been found to indicate side effects correlated with antidepressant

DocID: 1tkwO - View Document

Do not take extra medicine to treat tadalafil super active attention deficit hyperactivity disorder . an antidepressant--citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline. Answers from Donald Hens

DocID: 1sM49 - View Document

Medical research / Health / GlaxoSmithKline / Selective serotonin reuptake inhibitors / Medical ethics / Depression / Study 329 / Paroxetine / Martin Keller / Antidepressant / Journal of the American Academy of Child and Adolescent Psychiatry / Sertraline

International Journal of Risk & Safety in Medicine–81 DOIJRSIOS Press 73

DocID: 1roTK - View Document

Depression / Abnormal psychology / Psychiatry / Neurochemistry / Antidepressant / Major depressive disorder / Suicidal ideation / Management of depression / Antidepressants and suicide risk

Medication Guide Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions

DocID: 1rlMD - View Document